hereditary angieoedema

merger MA unit combine consolidate deal
Pharma

Chiesi grows rare disease ambitions with $1.9B KalVista buyout

As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare disease med and its developer KalVista.
Fraiser Kansteiner Apr 29, 2026 10:01am
FDA

KalVista secures rare disease approval following FDA delay

Jul 7, 2025 10:14am
Andembry

In competitive HAE market, CSL gains FDA approval for Andembry

Jun 17, 2025 11:10am
Road block challenges clinical hold problems

FDA slaps clinical hold on Pharvaris' HAE med

Aug 22, 2022 9:58am